Literature DB >> 10568823

In vivo radiosensitizing effect of the adenovirus E1A gene in murine and human malignant tumors.

P Martin-Duque1, R Sánchez-Prieto, J Romero, A Martinez-Lamparero, S Cebrian-Sagarriga, J Guinea-Viniegra, C Dominguez, M Lleonart, A Cano, M Quintanilla, S Ramón Y Cajal.   

Abstract

The adenovirus E1A gene is a potent inducer of chemosensitivity and radiosensitivity through p53-dependent and independent mechanisms. We have studied the sensitivity of murine (MSC11A5, a sarcomatoid epidermoid carcinoma) and human (HeLa, human cervix carcinoma) E1A-expressing tumors, in vivo, after treatment with cisplatin or gamma-irradiation. In athymic mice, half-body irradiation was performed in an AECL Cobalt unit, at an SSD of 80 cm. Daily fractions of 300 cGy over 3 days, up to a total dose of 9 Gy. Cisplatin was injected intraperitoneally at a dose of 9 mg per kg of body weight. After gamma-irradiation or intraperitoneal injection of cisplatin, about 30% of the E1A-expressing tumors regressed completely or were associated with a marked decrease in tumorigenicity over the following weeks. We conclude that malignant tumors, when expressing adenovirus E1A, are very sensitive to treatment with DNA-damaging agents, in vivo, regardless of the p53 status of the tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10568823     DOI: 10.3892/ijo.15.6.1163

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  Expression of p53 synergistically augments caspases-mediated apoptosis induced by replication-competent adenoviruses in pancreatic carcinoma cells.

Authors:  Y Takei; S Okamoto; K Kawamura; Y Jiang; T Morinaga; M Shingyoji; I Sekine; S Kubo; Y Tada; K Tatsumi; H Shimada; K Hiroshima; N Yamaguchi; M Tagawa
Journal:  Cancer Gene Ther       Date:  2015-08-07       Impact factor: 5.987

Review 2.  Adenoviral vectors for prodrug activation-based gene therapy for cancer.

Authors:  Joshua C Doloff; David J Waxman
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

3.  Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.

Authors:  Joshua C Doloff; David J Waxman; Youssef Jounaidi
Journal:  Hum Gene Ther       Date:  2008-12       Impact factor: 5.695

4.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

5.  Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.

Authors:  J C Doloff; Y Jounaidi; D J Waxman
Journal:  Cancer Gene Ther       Date:  2010-09-24       Impact factor: 5.987

6.  E1A enhances cellular sensitivity to DNA-damage-induced apoptosis through PIDD-dependent caspase-2 activation.

Authors:  Jay R Radke; Zeba K Siddiqui; Iris Figueroa; James L Cook
Journal:  Cell Death Discov       Date:  2016-10-31

Review 7.  Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.

Authors:  Chae-Ok Yun; JinWoo Hong; A-Rum Yoon
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

8.  Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts.

Authors:  B Geoerger; J Grill; P Opolon; J Morizet; G Aubert; Y Lecluse; V W van Beusechem; W R Gerritsen; D H Kirn; G Vassal
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.